Home Depot is a DJIA component and steady dividend payer. But do economic headwinds and a cooling housing sector pose threats to this retail icon and its payout? Read More
Analyst Articles
Pfizer is a growth-and-income stock found in many retirement portfolios. But is the competition from biotech "disruptors" getting too hot for this Big Pharma stalwart? Read More
Chevron is poised to gain from rising crude prices, but the energy sector remains volatile. Can this "super major" overcome the industry's uncertainties? Read More
As the largest health insurer in the U.S., UnitedHealth Group is poised to greatly benefit from booming health care expenditures. But do proposed government policy changes threaten the stock? Read More
Health services giant Johnson & Johnson has been a reliable growth-and-income stock for years, but can it overcome the scandal about its allegedly carcinogenic talcum powder? Read More
General Motors has proven itself a survivor, emerging from the federal government bailout in competitive shape. But disruptive technology and economic storm clouds now threaten this Detroit icon. Read More
Cash-rich tech titans such as Microsoft have become growth-and-income plays. But as headwinds mount for the tech sector, how safe is the firm's dividend? Read More
For this week’s Big Interview, we pose questions to Dr. Stephen Leeb, renowned investment analyst and best-selling author. Read More
BP is a high-yielding stock prized by investors who seek steady income. But amid the prolonged volatility of oil and gas prices, can this energy "super major" sustain its dividend? Read More
Apple has racked up phenomenal capital appreciation over the years, but many investors underappreciate its dividend growth potential. Here's why Apple is an income generator, too. Read More